What is KD-CAAP?
Kawasaki Disease Coronary Artery Aneurysm Prevention trial, or KD-CAAP is a clinical trial which has been designed by doctors to see if we can find better treatment for Kawasaki Disease in children.
With standard treatments, children with Kawasaki Disease have a very high risk of lifetime heart damage and doctors are working to find better treatments through KD-CAAP.
KD-CAAP is “a phase III multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD)”.
That’s the really technical description!! What that means is:
✅It’s a trial – or a way of comparing how good different medicines are when treating an illness
✅Both doctors and patients taking part will know which treatments are being given
✅ The end point is blinded which means that any potential heart damage will be assessed by someone who does not know what treatment the participant is receiving.
✅One extra medicine (corticosteroids) will be given to half of the children – with the other half getting the standard treatment they’d get anyway if we hadn’t decided to do this trial (or if they didn’t join the trial)
✅The overall conclusion of how effective the two treatments are will be decided at the end of the project, based on everything we find out
Why do doctors do clinical trials?
Whilst there are treatments available for most illnesses, doctors are always looking for ways to improve treatments.
Kawasaki Disease is no exception! The treatments for Kawasaki Disease haven’t really changed for a long time and recent research (UK and Ireland, but also elsewhere in Europe) shows that a very high proportion of children suffer serious heart damage, even when they receive the current recommended treatments.
Doctors in the U.K., working with Societi Foundation, agreed to develop a clinical trial to see if a better treatment could be found. The KD-CAAP trial is designed by doctors to investigate a better possible treatment for Kawasaki Disease.